Emcure Pharmaceuticals Ltd. reported a 22.8% year-on-year increase in consolidated revenue from operations to Rs 2,580.4 crore for the first quarter ended June 30, 2026, driven by strong momentum across international markets and steady growth in its domestic business.

The company posted EBITDA of Rs. 508 crore, up 25.8% year-on-year, with EBITDA margin improving 50 basis points to 19.7%. Profit after tax (PAT) rose 36.2% to Rs. 292.5 crore, while PAT margin expanded 110 basis points to 11.3%.

Satish Mehta, Managing Director and CEO, Emcure Pharmaceuticals, said, "We have begun FY27, the second year of our five-year plan—on a strong footing. FY26 was about putting the building blocks in place across teams, portfolio, integration and operating discipline. FY27 is about delivery, and Q1 is an encouraging early signal.”

“Revenue grew 22.8% year-on-year to Rs. 25,804 Mn and was supported by momentum across geographies. EBITDA grew 25.8% to Rs. 5,080 Mn, with margin improving to 19.7%, up ~50 basis points year-on-year, reflecting productivity gains and operating leverage. PAT grew faster at 36.2% to INR 2,925 Mn, underlining the strength of the quarter's operating performance,” added Mehta. 

The international business remained the primary growth driver, with revenue rising 34.2% year-on-year to Rs 1,485.1 crore, contributing 57.6% of consolidated revenue.

Within the international portfolio, Europe registered 32.8% growth to Rs 536.7 crore, supported by strong base business performance and increased contribution from Liposomal Amphotericin B. Canada recorded 24.6% growthto Rs 426.6 crore, while the Rest of the World business expanded 44.8% to Rs 521.8 crore, driven by strong performance in the antiretroviral (ARV) portfolio.

Emcure's domestic business grew 10.2% year-on-year to Rs. 1,095.3 crore, accounting for 42.4% of consolidated revenue. Growth was led by key brands in the central nervous system (CNS), cardiology and women's healthsegments, along with improved execution at Zuventus following organisational changes implemented over the previous two quarters.

The company invested Rs. 90.4 crore, or 3.5% of revenue, in research and development during the quarter and secured more than 15 product approvals across developed and emerging markets.

In July 2026, Emcure licensed SHetA2, a novel anti-HPV candidate for Cervical Intraepithelial Neoplasia (CIN), from the Indian Council of Medical Research (ICMR) under the Medical Innovations Patent Mitra initiative. The company will further develop the candidate as part of its women's health portfolio.